EPO and anemia (phenotype): In line with these findings, studies had shown that correction of anemia with high-dose recombinant human EPO in remnant kidney model resulted in hypertension and deterioration of renal function, possibly through activation of endothelin and renin-angiotensin system37, 38, 39.